clinical trial · NCT07305779
A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women
Otsuka Pharmaceutical Development & Commercialization, Inc.·phase1·completed·n = 12
SchizophreniaSEP-380135Quinidine Gluconate
brief summary
The purpose of this study is to assess the effect of cytochrome P450 isoenzyme 2D6 (CYP2D6) inhibition by quinidine on the pharmacokinetic (PK) parameters of a single dose SEP-380135 in healthy adult participants.
started
Mar 7, 2025
primary completion
May 3, 2025
completion
May 3, 2025
last updated
Jan 15, 2026
official title
A Phase 1, Open-label, Single-sequence Pharmacokinetic Trial to Assess the Effect of a Single Oral Dose of SEP-380135 on the Potential for Cytochrome P4502D6 Mediated Drug-drug Interactions in Healthy Adults
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol